Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome.

This Latin American research supported the use of teduglutide following the early identification of advantageous anatomy (partial colon in continuity) and reduced reliance on parenteral nutrition at baseline. The therapy was maintained for 24 weeks, with the evaluation commencing after 12 weeks of treatment, leading to total parenteral nutrition independence in 26.6% of patients. The reported adverse effects related to the treatment were minimal and aligned with those found in existing literature. Limitations of the study included limited patient recruitment, a lack of discussion regarding the actual treatment duration, no data on routine endoscopies/colonoscopies performed to detect tumor or polyp recurrence during treatment, and the cost implications of such treatment. In a recent article, the median time for adverse events to occur was 393 days (56 weeks). At the same time, the current study lasted 24 weeks, suggesting that theoretically, numerous adverse events may have gone unnoticed.